Werewolf announces preliminary Phase 1/1b data for WTX-124 showing proof of mechanism and early antitumor activity

Werewolf Therapeutics, Inc.

16 heavily pretreated patients in first four monotherapy dose cohorts (1-12 mg); no dose-limiting toxicities or VLS observed.
Two unconfirmed partial responses at 12 mg; one additional patient with evidence of antitumor activity.
CD8+ T and NK cell proliferation/activation in tumor microenvironment seen at 6 mg and 12 mg.
Dose escalation ongoing; cohort 5 (18 mg) fully enrolled; RDE and expansion arms expected H1 2024.
WTX-124 generally well-tolerated in outpatient setting with all TEAEs Grade 1-2.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.